Project Grant R21AG083589

Award Date 9/1/23
Completion Date 8/31/25
Dollars Obligated $428K
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Chapel Hill, NC 27599, USA
Similar Awards
The University of North Carolina at Chapel Hill will develop computational tools to harmonize multi-site neuroimaging data and enable personalized analysis of subjective cognitive decline and Alzheimer's disease-related disorders through a $2.8 million project grant from the National Institute on Aging. Under the award effective May 1, 2022, UNC-Chapel Hill will create machine learning frameworks for feature-level and image-level harmonization of data from 79 imaging centers involving over...
The University of North Carolina at Chapel Hill (UNC-CH) received a $2,278,406 Cooperative Agreement award from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) to conduct a 5-year study on proteomic biomarkers of cognitive impairment in Black and White adults. The project will assess 3,072 circulating plasma proteins, including over 700 inflammation-related proteins, to identify potential non-invasive biomarkers of Alzheimer's disease and related dementias...
This $2,151,878 federal Project Grant award, funded by the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), supports research at the University of North Carolina at Chapel Hill (UNC-CH) and its subrecipient, the University of Pennsylvania, to map the causal genetic-imaging-clinical pathway for Alzheimer's disease (AD). The key products and services to be delivered through this 3-year project include: Developing robust functional connectome analysis and...
This federal Project Grant award of $205,000 from the National Institute on Aging (CFDA 93.866 - Aging Research) supports the development of a Summer Research Education Program for Promoting Computational Neuroimaging Technology in Alzheimer's Disease (AD) and AD-Related Dementias (ADRD). The program aims to address the urgent need for a capable workforce with computational neuroimaging skillsets by providing high school students with a hybrid curriculum, hands-on tutorials, and a cloud-based...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $833,173 to the University of North Carolina at Chapel Hill (UNC-CH) to develop an optimized and cell-active chemical probe targeting the protein kinase CK2. The goal is to validate CK2 as a novel therapeutic target for treating Alzheimer's disease (AD) by demonstrating the probe's ability to modulate key pathogenic signaling pathways related to neuroinflammation in AD, without eliciting...
This $174,242 Project Grant award under the National Institute on Aging's Aging Research program (CFDA 93.866) aims to study the prefrontal microcircuit changes in the brain during healthy aging and Alzheimer's disease progression. The project will integrate empirical in vivo calcium imaging recordings, computational simulation modeling, and calcium imaging-based neural decoding methods to determine the impacts of normal aging and Alzheimer's-related pathologies on the prefrontal cortex...
This $416,750 federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to the University of North Carolina at Chapel Hill supports the development of a novel computational model to understand the control mechanisms underlying functional dynamics in the human brain. The key goals are to: 1) Uncover the characteristic equation of dynamical systems from functional connectivity (FC) data using a deep end-to-end neural network model, and 2) Measure brain...
The National Institute on Aging (NIA) awarded a $763,225 Cooperative Agreement (U01AG088667) under the Aging Research federal grant program (CFDA 93.866) to the University of North Carolina at Chapel Hill (UNC-CH) to conduct research on gene-environment interactions related to Alzheimer's disease (AD). The project aims to identify how common genetic variants and environmental exposures, such as air pollution, heavy metals, and infections, interact to influence neural cell function and...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $800,700 in funding to The Regents of the University of California, San Francisco (UCSF) to conduct a longitudinal, multimodal neuroimaging study exploring the role of neuronal dysfunction and hyperexcitability in the early biological progression of Alzheimer's disease. The study aims to elucidate the earliest manifestations of neural circuit hyperexcitability that predict the accumulation of...
The University of North Carolina at Chapel Hill (UNC-CH) received a $424,095 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to develop a CRISPR/Cas13 gene therapy targeting the tau protein for the treatment of Alzheimer's disease and other tauopathies. The project aims to identify and validate optimal guide RNAs to deplete specific tau isoforms in neurons, and evaluate the therapeutic potential of this approach in preclinical Alzheimer's disease mouse...

The University of North Carolina at Chapel Hill (UNC-CH) received a $427,625 Project Grant award from the National Institute on Aging under the Aging Research program (CFDA 93.866) to develop and validate a computational framework for identifying excitation-inhibition imbalances in Alzheimer's disease (AD) using multi-modal neuroimaging data. The goal is to create an innovative technique that can noninvasively detect circuit-level disruptions in brain networks associated with AD pathology, which may facilitate earlier diagnosis and targeted interventions. The project has two specific aims: 1) predicting disrupted excitation-inhibition balance in an AD mouse model using a multi-scale neural model inversion framework applied to resting-state functional MRI and diffusion MRI data, and 2) validating the model predictions through in vivo optical measurements and behavioral testing in mice. Successful completion of this 2-year effort could lead to the development of a diagnostic tool for identifying excitation-inhibition imbalances in AD patients.

Generated 8/13/24, 5:55 AM